Lilly's efficacy figure drops to 25.0% under the stricter analysis, 12% quit the 9 mg dose over side effects, and nobody yet knows what happens after stopping.
Recap by typeshit. Full story at nchstats.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
18:20
Dr. Lindsay Ogle, an MD who covers metabolic health, talks through options for people whose appetite hasn't settled on GLP-1 treatment.
A short post credits scientists with finding axolotl peptides that kill breast cancer cells. It names no study or team, so treat it as an early claim.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
A short local news segment checks the safety concerns around retatrutide, which is still in trials and not approved by the FDA.
PADCENS, the Philippine diabetes care nurse association, says it upholds ethical practice and patient safety. The excerpt never says what prompted it.
Loading…